Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Nilanjan Banerjee headshot

Coronavirus Drug & Vaccine: 4 Companies Leading From the Front

by Nilanjan Banerjee

The present scenario has brightened up prospects for companies working on potential drugs and vaccines to combat the pandemic.

Zacks Equity Research

Is the Options Market Predicting a Spike in Moderna (MRNA) Stock?

by Zacks Equity Research

Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna, Regeneron, Zoom Video, Netflix and Peloton

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna, Regeneron, Zoom Video, Netflix and Peloton

Ekta Bagri headshot

Coronavirus Vaccine Race Intensifies: 3 Stocks in Focus

by Ekta Bagri

Given the urgent need for preventing the spread of COVID-19 in future, let's take a look at the companies developing vaccines for the same.

Sweta Jaiswal, FRM headshot

Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development

by Sweta Jaiswal, FRM

The rampant race to introduce a vaccine for the COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.

Zacks Equity Research

Is Moderna (MRNA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (MRNA) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Will Moderna Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Moderna

Tirthankar Chakraborty headshot

Top Stock Trades to Beat Coronavirus Blues in April

by Tirthankar Chakraborty

The coronavirus pandemic has hit markets bad. But investors shouldn't shun stocks in April but should instead look for avenues to invest in areas under focus owing to rise in infected cases.

Zacks Equity Research

Moderna (MRNA) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed the most recent trading day at $30.48, moving +1.43% from the previous trading session.

Zacks Equity Research

Translate Bio, Sanofi to Jointly Develop Coronavirus Vaccine

by Zacks Equity Research

Translate Bio (TBIO) gains on collaboration with Sanofi for a mRNA vaccine development for COVID-19.